Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoric diester hydrolases, commonly known as phosphodiesterases (PDEs), are a class of enzymes that catalyze the hydrolysis of phosphodiester bonds. They play a crucial role in regulating intracellular signaling by controlling the levels of cyclic nucleotides (cAMP and cGMP). There are at least 11 different mammalian PDE families, each with varying substrate specificities, tissue distributions, and regulatory properties. PDEs are important therapeutic targets, with inhibitors used to treat various diseases, including cardiovascular disorders and erectile dysfunction.
Inhibition of phosphodiesterase activity, leading to increased levels of cAMP or cGMP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoric Diester Hydrolase (PDE).